Тамар Перец

Научные публикации

• "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis"
• A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer
• Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
• Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
• Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer
• Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
• ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
• Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1/2 Germline Mutations: Report of Ten Cases and a Literature Review
• Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer
• Splicing Factor Transcript Abundance in Saliva as a Diagnostic Tool for Breast Cancer
• Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants
• Correction: Exclusive destruction of mitotic spindles in human cancer cells
• Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
• SLAMF6​ deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
• Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective Study
• Author Correction: Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
• Regulation of Heparanase in Diabetes-Associated Pancreatic Carcinoma
• Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes
• Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization
• Heparanase Accelerates Obesity-Associated Breast Cancer Progression
• The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients
• Variable Features of Juvenile Polyposis Syndrome With Gastric Involvement Among Patients With a Large Genomic Deletion of BMPR1A
• Life and death of circulating cell-free DNA
• Lacosamide at therapeutic concentrations induces histone hyperacetylation in vitro
• Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells
• Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40
• Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer
• Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification
• Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study
• The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations
• Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report
• SYK expression level distinguishes control from BRCA1-mutated lymphocytes
• Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy
• Breast cancer among older women: The influence of age and cancer stage on survival
• Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
• Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers
• BRCA mutations and reproduction
• Soluble SLAMF6 Receptor Induces Strong CD8⁺ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo
• p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial
• Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
• Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
• Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis
• Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance
• Exclusive destruction of mitotic spindles in human cancer cells
• Adoptive cell therapy: past, present and future
• Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer
• Heparanase augments insulin receptor signaling in breast carcinoma
• Spontaneous Activation of Antigen-presenting Cells by Genes Encoding Truncated Homo-Oligomerizing Derivatives of CD40
• Erratum to: Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer
• Recurrent TP53 missense mutation in cancer patients of Arab descent